Our results also have implications for ongoing clinical trials of cancer nanomedicines, as they describe how TGF‐β inhibition can normalize metastases and in turn improve nanocarrier efficacy to metastatic breast cancer and stimulate anti‐tumor immune responses. This evidence concerns the gene TGFB1 and neoplasm.